Last $4.62 USD
Change Today +0.07 / 1.54%
Volume 7.7K
TLOG On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 11:09 AM 12/29/14 All times are local (Market data is delayed by at least 15 minutes).

tetralogic pharmaceuticals c (TLOG) Snapshot

Open
$4.53
Previous Close
$4.55
Day High
$4.69
Day Low
$4.46
52 Week High
01/15/14 - $14.75
52 Week Low
10/13/14 - $3.51
Market Cap
103.1M
Average Volume 10 Days
129.8K
EPS TTM
--
Shares Outstanding
22.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TETRALOGIC PHARMACEUTICALS C (TLOG)

Related News

No related news articles were found.

tetralogic pharmaceuticals c (TLOG) Related Businessweek News

No Related Businessweek News Found

tetralogic pharmaceuticals c (TLOG) Details

TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical company in the United States. The company focuses on discovering and developing novel small molecule therapeutics that mimic novel second mitochondrial activator of caspases to cause or enable abnormal cells, which are resistant to the body’s immune system to self-destruct. Its clinical-stage product candidate, Birinapant, is in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The company’s clinical and pre-clinical programs comprise an ongoing Phase I/II clinical trial of birinapant as a single agent in various blood cancers; a Phase I/II completed clinical trial of birinapant administered with irinotecan in colorectal cancer; and a Phase I/II clinical trial of birinapant administered with conatumumab in ovarian cancer, as well as an intention to start Phase I clinical trial in hepatitis B virus. It has collaboration with Amgen, Inc. for exploring the combination of birinapant administered with Amgen’s TRAIL receptor agonist antibody, conatumumab. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

20 Employees
Last Reported Date: 03/19/14
Founded in 2001

tetralogic pharmaceuticals c (TLOG) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $175.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $141.2K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $137.2K
Chief Scientific Officer
Total Annual Compensation: $315.2K
Compensation as of Fiscal Year 2013.

tetralogic pharmaceuticals c (TLOG) Key Developments

TetraLogic Pharmaceuticals Corporation Announces Initiation of Randomized Phase 2 Clinical Trial of Shape in Subjects with Cutaneous T-Cell Lymphoma

TetraLogic Pharmaceuticals Corporation announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous Tcell lymphoma. SHAPE has been evaluated in a randomized, dose escalation, placebo-controlled Phase 1 clinical trial in early-stage CTCL subjects that met safety endpoints and demonstrated clinical activity. Four of fifteen patients receiving SHAPE attained an objective response as measured by a greater than 50% improvement in their Composite Assessment of Index Lesion Severity, or CAILS, score during and after 28 days of dosing. No placebo patients responded. The randomized Phase 2 trial will be conducted in approximately sixty subjects with Stage IA-IIA CTCL. The objectives of the Phase 2 clinical trial are to evaluate the dose, clinical effect at 6 months (based on CAILS score), time to response, and tolerability of treatment of >2% body surface area.

TetraLogic Pharmaceuticals Corporation Provides Update on Ovarian Cancer Study

TetraLogic Pharmaceuticals Corporation announced that it intends to proceed with the expansion phase of its study in patients with ovarian cancer. The study is being conducted in patients who have failed up to three rounds of prior chemotherapy. In the study birinapant has been dosed twice weekly, 3 weeks out of 4, or 4 weeks out of 4, in combination with Amgen's TRAIL receptor 2 agonist antibody, conatumumab, dosed every 2 weeks. To date eighteen patients have been dosed in the Phase 1b portion of the study. Results thus far suggest a pharmacodynamic interaction between the two drugs, manifested as the appearance of adverse events at lower than anticipated doses. In addition, one patient showed a partial response and two patients have maintained stable disease, one through four cycles of treatment, and one through two. Three additional patients are on study awaiting scans.

TetraLogic Pharmaceuticals Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 10:00 AM

TetraLogic Pharmaceuticals Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 10:00 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: C. Glenn Begley, Chief Scientific Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TLOG:US $4.62 USD +0.07

TLOG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TLOG.
View Industry Companies
 

Industry Analysis

TLOG

Industry Average

Valuation TLOG Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TETRALOGIC PHARMACEUTICALS C, please visit www.tetralogicpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.